Want to see RARE full AI Analyst Report?

Ultragenyx Pharmaceutical (RARE) Price & Analysis

1,315 Followers

RARE Stock Chart & Stats

$26.46

-$0.16(-0.59%)

At close: Jul 27 4:00 PM EDT

$26.46

-$0.16(-0.59%)

Day’s Range― - ―

52-Week Range$12.73 - $39.89

Previous CloseN/A

Volume170.99K

Average Volume (3M)5.04M

Market Cap

$1.57B

Enterprise Value$4.31B

Total Cash (Recent Filing)$292.00M

Total Debt (Recent Filing)$1.20B

Price to Earnings (P/E)―

Beta1.44

Next Earnings

Nov 04, 2026

EPS Estimate

-1.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.84

Shares Outstanding98,588,875

10 Day Avg. Volume3,678,105

30 Day Avg. Volume5,038,245

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)-28.35

Price to Sales (P/S)3.37

P/FCF Ratio-4.80

Enterprise Value/Market Cap2.75

Enterprise Value/Revenue6.01

Enterprise Value/Gross Profit7.23

Enterprise Value/Ebitda-9.11

Forecast

1Y Price Target

$26.25

Price Target Upside-0.79% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering21

EPS Forecast (FY)-4.62

Revenue Forecast (FY)$751.44M

Bulls Say, Bears Say

Bulls Say

Revenue Scale And Gross MarginsRapid revenue expansion combined with consistently high gross margins indicates strong economics in the commercial rare-disease portfolio. This gives Ultragenyx meaningful gross profit to reinvest in launches and pipeline programs, although operating costs currently absorb those gains.

FDA Approvals And Non-dilutive CapitalFAYUVI approval expands the commercial rare-disease portfolio while the associated voucher monetization provides substantial non-dilutive capital. This demonstrates that regulatory success can create both product opportunities and funding resources for operations, launches, and future pipeline investment.

Commercial Growth And Cost DisciplineRecord quarterly revenue and broad product growth show increasing commercial traction across the portfolio, while planned expense reductions could improve operating leverage. If double-digit growth and disciplined spending continue, the company has a clearer route toward its stated 2027 profitability objective.

Bears Say

Persistent Losses And Cash BurnLarge recurring cash outflows mean Ultragenyx is not yet self-funding its operations despite revenue growth and high gross margins. Continued losses can require external financing or asset monetization, potentially limiting investment flexibility and making the path to profitability dependent on substantial improvement.

Negative Equity And Leverage RiskNegative equity and the reported debt increase materially weaken financial flexibility. A more leveraged capital structure can constrain spending choices, increase refinancing exposure, and leave fewer balance-sheet resources available to absorb clinical setbacks or slower-than-planned product adoption.

Pipeline Execution And Approval DependenceThe Aspire failure highlights the binary risk of developing therapies for rare and ultra-rare diseases, where a single late-stage setback can reduce pipeline value and force resource reallocation. Near-term growth plans also remain exposed to uncertain regulatory and clinical outcomes.

Ultragenyx Pharmaceutical News

Ultragenyx initiated with a Neutral at UBS

UBS initiated coverage of Ultragenyx (RARE) with a Neutral rating and $16 price target Two recent approvals, Fayuvi...

8d ago

RARE

Ultragenyx to sell Rare Pediatric Disease PRV for $203M

Ultragenyx (RARE) announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority...

8d ago

RARE

Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $210M

Ultragenyx (RARE) announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority...

15d ago

RARE

Ultragenyx call volume above normal and directionally bullish

Bullish option flow detected in Ultragenyx (RARE) with 14,548 calls trading, 2x expected, and implied vol increasing almost...

29d ago

RARE

Ultragenyx, Baylor Reach Settlement on DOJOLVI Patents

Ultragenyx Pharmaceutical ( ($RARE) ) has shared an announcement. On October 19, 2026, Ultragenyx Pharmaceutical Inc. and Baylor...

3d ago

RARE

Ultragenyx: Non-Dilutive Capital and Clinical Catalysts Underscore Buy Rating and Unchanged $25 Price Target

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ultragenyx Pharmaceutical, with...

8d ago

RARE

Ultragenyx Sells FDA Priority Review Voucher for Cash

Ultragenyx Pharmaceutical ( ($RARE) ) has shared an announcement. On October 8, 2026, Ultragenyx Pharmaceutical Inc. agreed to...

8d ago

RARE

Ultragenyx Monetizes FDA Priority Review Voucher Asset

Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On October 6, 2026, Ultragenyx Pharmaceutical Inc. entered into...

15d ago

RARE

Ultragenyx Launches 10-Year Gene Therapy Monitoring Program for MPS IIIA

Ultragenyx Pharmaceutical, Inc. ($RARE) announced an update on their ongoing clinical study. The Mucopolysaccharidosis Type IIIA (MPS IIIA)...

20d ago

RARE

Ultragenyx: FDA Gene Therapy Progress and Upcoming Pivotal Readouts Support Buy Rating with Unchanged $25 Price Target

Ultragenyx Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

27d ago

RARE

Ultragenyx price target raised to $18 from $16 at Evercore ISI

Evercore ISI raised the firm’s price target on Ultragenyx (RARE) to $18 from $16 and keeps an In...

1M ago

RARE

Ultragenyx price target raised to $35 from $32 at Barclays

Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating...

1M ago

RARE

Ultragenyx price target raised to $20 from $18 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Ultragenyx (RARE) to $20 from $18 and keeps an Equal...

1M ago

RARE

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI,...

1M ago

ABEO

RARE

RARE FAQ

What was Ultragenyx Pharmaceutical’s price range in the past 12 months?

Ultragenyx Pharmaceutical lowest stock price was $12.73 and its highest was $39.89 in the past 12 months.

What is Ultragenyx Pharmaceutical’s market cap?

Ultragenyx Pharmaceutical’s market cap is $1.57B.

When is Ultragenyx Pharmaceutical’s upcoming earnings report date?

Ultragenyx Pharmaceutical’s upcoming earnings report date is Nov 04, 2026 which is in 13 days.

How were Ultragenyx Pharmaceutical’s earnings last quarter?

Ultragenyx Pharmaceutical released its earnings results on Aug 04, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.318.

Is Ultragenyx Pharmaceutical overvalued?

According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ultragenyx Pharmaceutical pay dividends?

Ultragenyx Pharmaceutical does not currently pay dividends.

What is Ultragenyx Pharmaceutical’s EPS estimate?

Ultragenyx Pharmaceutical’s EPS estimate is -1.11.

How many shares outstanding does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical has 98,588,875 shares outstanding.

What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?

Ultragenyx Pharmaceutical reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -3.41%.

Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?

Currently, no hedge funds are holding shares in RARE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ultragenyx Pharmaceutical Stock Smart Score

Neutral

Fundamentals

Return on Equity

392.35%

Trailing 12-Months

Asset Growth

-3.24%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ultragenyx Pharmaceutical (RARE) Earnings & Revenues

Historic Earnings Reports

RARE Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.View all RARE earnings summaries

RARE Stock 12 Month Forecast

Average Price Target

$26.25

▼(-0.79% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","40":"$40","19.75":"$19.75","26.5":"$26.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,19.75,26.5,33.25,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.75,16.615384615384617,18.48076923076923,20.346153846153847,22.21153846153846,24.076923076923077,25.942307692307693,27.807692307692307,29.673076923076923,31.53846153846154,33.40384615384615,35.269230769230774,37.13461538461539,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.75,15.634615384615385,16.51923076923077,17.403846153846153,18.28846153846154,19.173076923076923,20.057692307692307,20.942307692307693,21.826923076923077,22.71153846153846,23.596153846153847,24.48076923076923,25.365384615384613,{"y":26.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.75,14.846153846153847,14.942307692307692,15.038461538461538,15.134615384615385,15.23076923076923,15.326923076923077,15.423076923076923,15.51923076923077,15.615384615384615,15.711538461538462,15.807692307692308,15.903846153846153,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.81,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >